Skip to main content
Go to the home page of the European Commission (opens in new window)
English en
CORDIS - EU research results
CORDIS

Determining Genetic Bases of Differential Response to Antipsychotics Using Patient-Derived Neurons

Project description

Schizophrenia models unveil therapeutic biomarkers

Schizophrenia is a mental disorder associated with a perturbed interpretation of reality and patients experience hallucinations and delusions. As it is not possible to stratify schizophrenia patients, they all receive antipsychotic drugs as a first-line treatment with suboptimal results. Funded by the Marie Skłodowska-Curie Actions programme, the MapGen project aims to delineate the neuronal pathways responsible for schizophrenia pathophysiology. Researchers will develop neurodevelopmental models from patient stem cells and investigate their molecular and genetic profile. Results will also help understand the different response to treatment among schizophrenia patients, paving the way for more tailored interventions.

Objective

Schizophrenia (SCZ) affects 20 million people worldwide and antipsychotics remain the only effective pharmacological intervention. However, one-third of people with SCZ do not respond to first-line antipsychotic drugs. In the absence of clinical biomarkers to stratify SCZ subtypes, all individuals receive the same initial intervention, and it takes >4 years on average before people with resistant forms of the condition receive suitable treatment.

My overall aim is to unravel the pre-symptomatic cell-type-specific genetic circuits contributing to differential treatment response in SCZ. To achieve my aim I will use an interdisciplinary approach that improves my technical and soft skills and further extends my international network through a two-year stay at Yale University, and three months secondment at Harvard Medical School. During the return phase, I will establish myself as an independent researcher and a suitable candidate for leadership of a to-be-established stem cell lab at the host institute.

Objectives are (O1) to identify cell-type-specific neuronal pathways associated with distinct neurotransmission imbalances in each SCZ subgroup using a human-based neurodevelopmental model. (O2) To determine the functional link between SCZ-associated risk variants and response to antipsychotics.

Method: I will couple advanced stem cell models (region-specific brain organoids) with single-cell RNA sequencing to generate cell-type-specific transcriptomic profiles of patient-derived brain organoids from treatment-responsive and treatment-resistant forms of SCZ. I will integrate the potential risk variants from SCZ-GWAS and use published functional genomics data to determine the genetic pathways and associated regulators implicated in the etiopathophysiology of differential response to antipsychotics.

Impact: identify distinct genetic makeup for each SCZ subgroup to serve as potential predictive biomarkers and points of therapeutic intervention.

Fields of science (EuroSciVoc)

Keywords

Programme(s)

Topic(s)

Funding Scheme

HORIZON-TMA-MSCA-PF-GF - HORIZON TMA MSCA Postdoctoral Fellowships - Global Fellowships

See all projects funded under this funding scheme

Call for proposal

(opens in new window) HORIZON-MSCA-2021-PF-01

See all projects funded under this call

Coordinator

HELSE BERGEN HF
Net EU contribution
€ 307 939,68
Address
HAUKELANDSVEIEN 22
5021 Bergen
Norway
Region
Norge Vestlandet Vestland
Activity type
Higher or Secondary Education Establishments
Links
Total cost
No data

Partners (1)